Your browser is no longer supported. Please, upgrade your browser.
Settings
SNSS Sunesis Pharmaceuticals, Inc. daily Stock Chart
SNSS [NASD]
Sunesis Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.80 Insider Own0.10% Shs Outstand59.20M Perf Week5.72%
Market Cap31.29M Forward P/E- EPS next Y-0.77 Insider Trans208.33% Shs Float52.72M Perf Month-22.26%
Income-27.20M PEG- EPS next Q-0.21 Inst Own35.50% Short Float0.89% Perf Quarter-59.34%
Sales0.20M P/S156.47 EPS this Y40.30% Inst Trans-0.19% Short Ratio0.71 Perf Half Y-74.71%
Book/sh-0.32 P/B- EPS next Y-7.50% ROA-103.80% Target Price- Perf Year-91.22%
Cash/sh0.34 P/C1.55 EPS next 5Y- ROE393.60% 52W Range0.20 - 7.69 Perf YTD27.16%
Dividend- P/FCF- EPS past 5Y23.40% ROI-447.00% 52W High-93.13% Beta2.43
Dividend %- Quick Ratio1.70 Sales past 5Y-29.20% Gross Margin- 52W Low164.30% ATR0.06
Employees34 Current Ratio1.70 Sales Q/Q- Oper. Margin- RSI (14)54.83 Volatility7.67% 10.72%
OptionableYes Debt/Eq- EPS Q/Q58.00% Profit Margin- Rel Volume0.33 Prev Close0.53
ShortableYes LT Debt/Eq- EarningsMar 07 AMC Payout- Avg Volume665.68K Price0.53
Recom2.00 SMA202.27% SMA5011.21% SMA200-68.17% Volume217,102 Change-0.26%
Dec-20-18Initiated H.C. Wainwright Neutral
Dec-11-17Upgrade Wells Fargo Market Perform → Outperform
Dec-05-17Downgrade Wells Fargo Outperform → Market Perform
Jul-29-16Upgrade Wells Fargo Market Perform → Outperform
Jul-24-15Downgrade ROTH Capital Buy → Sell $5.50 → $1
Jul-24-15Downgrade Cantor Fitzgerald Buy → Hold
Jun-15-15Reiterated ROTH Capital Buy $4 → $5.50
May-05-15Reiterated ROTH Capital Buy $4.30 → $4
Dec-15-14Upgrade ROTH Capital Neutral → Buy $2.30 → $4.30
Dec-09-14Reiterated ROTH Capital Neutral $1.30 → $2.30
Oct-07-14Downgrade ROTH Capital Buy → Neutral $15 → $1.30
Oct-07-14Downgrade RBC Capital Mkts Outperform → Sector Perform $9 → $3
Jun-12-14Initiated UBS Buy $14
Sep-11-12Reiterated Cantor Fitzgerald Buy $6 → $8
May-29-12Upgrade RBC Capital Mkts Sector Perform → Outperform $3 → $5
Apr-13-12Initiated Cantor Fitzgerald Buy $6
Mar-06-12Initiated Canaccord Genuity Buy $4
Oct-11-11Downgrade RBC Capital Mkts Outperform → Sector Perform $4 → $3
Sep-29-11Initiated MLV Capital Buy $3.50
Feb-15-19 02:25PM  Agios (AGIO) Q4 Earnings Beat, Tibsovo Sales Push Up Stock Zacks
10:29AM  Acorda (ACOR) Q4 Earnings and Revenues Surpass Estimates Zacks
Jan-18-19 07:49AM  The Daily Biotech Pulse: Regulatory Roadblock For Immunomedics, AdCom Split On Lexicon's Diabetes Drug Benzinga -19.82%
Jan-17-19 09:58PM  Sunesis Announces Pricing of $20 Million Offering of Securities GlobeNewswire -13.43%
04:05PM  Sunesis Announces Proposed Public Offering of Common Stock and Preferred Stock GlobeNewswire
Jan-02-19 07:00AM  Sunesis Pharmaceuticals Announces Advancement into 100mg Cohort of Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies GlobeNewswire +5.85%
Dec-17-18 06:37PM  Edited Transcript of SNSS earnings conference call or presentation 5-Nov-18 9:30pm GMT Thomson Reuters StreetEvents -12.90%
Dec-04-18 07:59AM  The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO Benzinga
Dec-02-18 12:00PM  Sunesis Pharmaceuticals Announces Presentation of Preliminary Data from Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies at ASH Annual Meeting GlobeNewswire
Nov-29-18 08:06AM  Zacks.com highlights: Asbury Automotive, OncoGenex Pharmaceuticals, aTyr Pharma, Avinger and Sunesis Pharmaceuticals Zacks
Nov-28-18 07:04AM  5 Top-Ranked Rising P/E Stocks to Lure Investors Zacks +7.72%
07:00AM  Sunesis Pharmaceuticals to Provide Program Update for Non-Covalent BTK-Inhibitor Vecabrutinib at Analyst & Investor Event during ASH 2018 GlobeNewswire
Nov-19-18 07:00AM  Sunesis Pharmaceuticals to Present at the 30th Annual Piper Jaffray Healthcare Conference GlobeNewswire -8.13%
Nov-15-18 08:15AM  Report: Developing Opportunities within NeuroMetrix, Sunesis Pharmaceuticals, Siga Technologies, NexPoint Residential Trust, Frequency Electronics, and Horizon Technology Finance Future Expectations, Projections Moving into 2018 GlobeNewswire +8.70%
Nov-05-18 06:28PM  Sunesis: 3Q Earnings Snapshot Associated Press
04:05PM  Sunesis Pharmaceuticals Reports Third Quarter 2018 Financial Results and Recent Highlights GlobeNewswire
Nov-01-18 09:17AM  Sunesis Pharmaceuticals Announces Presentations at 60th American Society of Hematology Annual Meeting GlobeNewswire -7.14%
Oct-29-18 07:00AM  Sunesis Pharmaceuticals to Host Conference Call on November 5th to Discuss Third Quarter 2018 Financial Results and Recent Highlights GlobeNewswire -5.63%
Sep-26-18 07:00AM  Sunesis Pharmaceuticals to Present at the 2018 Cantor Global Healthcare Conference GlobeNewswire
Sep-12-18 11:56AM  Should You Worry About The Sunesis Pharmaceuticals Incs (NASDAQ:SNSS) Shareholder Register? Simply Wall St.
Sep-06-18 02:02PM  Edited Transcript of SNSS earnings conference call or presentation 7-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Aug-30-18 07:00AM  Sunesis Pharmaceuticals to Present at the Wells Fargo Securities 2018 Healthcare Conference GlobeNewswire +5.88%
Aug-07-18 07:13PM  Sunesis: 2Q Earnings Snapshot Associated Press
04:05PM  Sunesis Pharmaceuticals Reports Second Quarter 2018 Financial Results and Recent Highlights GlobeNewswire
Jul-31-18 07:00AM  Sunesis Pharmaceuticals to Host Conference Call on August 7th to Discuss Second Quarter 2018 Financial Results and Recent Highlights GlobeNewswire
Jul-09-18 07:00AM  Sunesis Pharmaceuticals Strengthens Senior Management Team GlobeNewswire +13.74%
Jun-25-18 04:10PM  Sunesis Pharmaceuticals Enters into $15.5 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC GlobeNewswire
Jun-18-18 07:00AM  Sunesis Pharmaceuticals Announces Presentations at the EHA Annual Meeting GlobeNewswire
Jun-15-18 09:13AM  5 Biotech Stocks Under $10 Worthy of Investors' Attention Zacks
May-14-18 11:42AM  Edited Transcript of SNSS earnings conference call or presentation 8-May-18 8:30pm GMT Thomson Reuters StreetEvents
May-08-18 04:46PM  Sunesis: 1Q Earnings Snapshot Associated Press -5.71%
04:00PM  Sunesis Pharmaceuticals Reports First Quarter 2018 Financial Results and Recent Highlights GlobeNewswire
May-01-18 04:05PM  Sunesis Pharmaceuticals to Host Conference Call on May 8th to Discuss First Quarter 2018 Financial Results and Recent Highlights GlobeNewswire
Apr-09-18 08:56AM  Are Options Traders Betting on a Big Move in Sunesis Pharmaceuticals (SNSS) Stock? Zacks
Mar-14-18 04:05PM  Sunesis Pharmaceuticals to Present at Upcoming Investor Conferences GlobeNewswire -15.67%
Mar-13-18 07:00AM  Sunesis Pharmaceuticals Announces Cancellation of Presentation and Webcast at Cowen & Company 38th Annual Health Care Conference GlobeNewswire
Mar-09-18 04:11PM  Edited Transcript of SNSS earnings conference call or presentation 8-Mar-18 9:30pm GMT Thomson Reuters StreetEvents -42.39%
Mar-08-18 06:54PM  Sunesis reports 4Q loss Associated Press
04:05PM  Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Highlights GlobeNewswire
01:00PM  Sunesis Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
10:25AM  Sunesis Pharmaceuticals Q4 Earnings Preview Benzinga
Mar-07-18 06:11AM  Are Earnings Prospects Improving For Loss-Making Sunesis Pharmaceuticals Incs (NASDAQ:SNSS)? Simply Wall St.
Mar-06-18 07:00AM  Sunesis Pharmaceuticals to Present at the Cowen and Company 38th Annual Health Care Conference GlobeNewswire
Mar-01-18 07:00AM  Sunesis Pharmaceuticals to Host Conference Call on March 8th to Discuss Fourth Quarter and Full-Year 2017 Financial Results and Recent Highlights GlobeNewswire
Feb-07-18 04:05PM  Sunesis Pharmaceuticals Appoints Industry Veteran H. Ward Wolff to the Board of Directors GlobeNewswire
Dec-05-17 07:00AM  Sunesis Pharmaceuticals to Provide Program Update for Non-Covalent BTK Inhibitor SNS-062 at Analyst & Investor Event during ASH 2017 GlobeNewswire -11.48%
Dec-04-17 04:05PM  Sunesis Pharmaceuticals Announces Change in Leadership GlobeNewswire
Nov-30-17 04:25PM  Edited Transcript of SNSS earnings conference call or presentation 2-Nov-17 6:00pm GMT Thomson Reuters StreetEvents
07:00AM  Sunesis Pharmaceuticals Appoints William Quinn as Chief Financial Officer and Senior Vice President, Finance and Corporate Development GlobeNewswire
Nov-16-17 08:00AM  Edison Issues Outlook on Sunesis Pharmaceuticals (SNSS) ACCESSWIRE
Nov-02-17 09:47AM  Sunesis reports 3Q loss Associated Press +10.88%
07:00AM  Sunesis Pharmaceuticals Reports Third Quarter 2017 Financial Results and Recent Highlights GlobeNewswire
Oct-27-17 07:00AM  Sunesis to Host Conference Call on November 2nd to Discuss Third Quarter 2017 Financial Results and Recent Highlights GlobeNewswire
Oct-25-17 08:54AM  Sunesis Announces Pricing of $20 Million Offering of Securities GlobeNewswire +11.89%
Oct-24-17 04:05PM  Sunesis Announces Proposed Public Offering of Common Stock, Preferred Stock and Warrants GlobeNewswire
Oct-03-17 09:36AM  Zacks.com featured highlights include MINDBODY, TearLab, Sunesis Pharmaceuticals, Children's Place, Franklin Electric Zacks
Oct-02-17 06:21AM  Step Beyond Bargain Hunting: 5 Stocks With Rising P/E Zacks
Aug-31-17 07:00AM  Sunesis to Present at Upcoming Investor Conferences GlobeNewswire
Aug-13-17 09:25AM  Edited Transcript of SNSS earnings conference call or presentation 27-Jul-17 6:00pm GMT Thomson Reuters StreetEvents
Jul-27-17 02:53PM  Sunesis reports 2Q loss Associated Press
07:00AM  Sunesis Pharmaceuticals Reports Second Quarter 2017 Financial Results and Recent Highlights GlobeNewswire
Jul-24-17 07:00AM  Sunesis to Host Conference Call on July 27th to Discuss Second Quarter 2017 Financial Results and Recent Highlights GlobeNewswire
Jul-18-17 04:05PM  Sunesis Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 Study Evaluating Oral Non-Covalent BTK-inhibitor SNS-062 in Adults with Chronic Lymphocytic Leukemia and other B-Cell Malignancies GlobeNewswire
Jun-26-17 07:00AM  Sunesis Pharmaceuticals Added to Russell Microcap® Index GlobeNewswire
Jun-23-17 07:00AM  Sunesis Pharmaceuticals Announces Presentation of Updated Results from Washington University-Sponsored Phase 1/Cohort Expansion Trial of Vosaroxin Plus Azacitidine in Patients with MDS at the EHA Annual Meeting GlobeNewswire +7.41%
May-19-17 06:18PM  IMPORTANT INVESTOR ALERT: Lundin Law PC Announces an Investigation of Sunesis Pharmaceuticals, Inc. and Advises Investors with Losses to Contact the Firm Business Wire
08:45AM  The Life Sciences Report Examines How Sunesis Pharmaceuticals Shifts Focus to Leukemia Drug Marketwired
May-15-17 07:08PM  Lifshitz & Miller LLP Announces Investigation of Anadarko Petroleum Corporation, DryShips Inc., ImmunoCellular Therapeutics, Ltd., KBR, Inc., Sunesis Pharmaceuticals, Inc., Sunrun Inc. and Vince Holding Corp. PR Newswire
May-12-17 11:05PM  Edited Transcript of SNSS earnings conference call or presentation 8-May-17 6:00pm GMT Thomson Reuters StreetEvents
May-11-17 05:32PM  ETFs with exposure to Sunesis Pharmaceuticals, Inc. : May 11, 2017 Capital Cube
May-10-17 10:25AM  Sunesis Pharmaceuticals, Inc. :SNSS-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017 Capital Cube
May-08-17 09:00AM  Investor Network: Sunesis Pharmaceuticals, Inc. to Host Earnings Call Accesswire
07:04AM  Sunesis reports 1Q loss Associated Press
07:00AM  Sunesis Pharmaceuticals Reports First Quarter 2017 Financial Results and Recent Highlights GlobeNewswire
May-04-17 02:49PM  IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Sunesis Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm Business Wire
May-03-17 06:47PM  INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Sunesis Pharmaceuticals, Inc. Investors Business Wire
01:27PM  IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Sunesis Pharmaceuticals, Inc. and Advises Investors with Losses to Contact the Firm Business Wire
11:54AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Sunesis Pharmaceuticals Inc. Business Wire
08:15AM  Blog Coverage Sunesis Pharma Withdraws European Marketing Authorization Application for Vosaroxin Accesswire
May-02-17 08:44PM  INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Sunesis Pharmaceuticals, Inc. Business Wire -18.99%
08:39PM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Sunesis Pharmaceuticals, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
06:38PM  SUNESIS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Sunesis Pharmaceuticals Inc. To Contact The Firm PR Newswire
03:47PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sunesis Pharmaceuticals, Inc. - SNSS PR Newswire
03:21PM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Sunesis Pharmaceuticals, Inc. (SNSS) PR Newswire
May-01-17 05:47PM  Sunesis shares drop as biotech drops leukemia drug marketing application MarketWatch -5.43%
04:30PM  Sunesis Pharmaceuticals Announces Withdrawal of European Marketing Authorization Application (MAA) for Vosaroxin as a Treatment for Relapsed/Refractory AML GlobeNewswire
Apr-03-17 08:00AM  Sunesis Pharmaceuticals Announces Presentation of The Ohio State University-Sponsored Preclinical Study of BTK Inhibitor SNS-062 at AACR Annual Meeting GlobeNewswire
Mar-28-17 07:00AM  Sunesis Pharmaceuticals to Present at the 16th Annual Needham Healthcare Conference GlobeNewswire
Mar-27-17 04:35PM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E
Mar-22-17 07:00AM  Sunesis Pharmaceuticals Announces Submission of Responses to the EMA Day 180 List of Outstanding Issues for Marketing Authorization Application for Vosaroxin GlobeNewswire
Mar-20-17 08:33AM  Sunesis Pharmaceuticals, Inc. :SNSS-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017 Capital Cube
08:33AM  Sunesis Pharmaceuticals, Inc. :SNSS-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
Mar-15-17 01:04PM  SUNESIS PHARMACEUTICALS INC Financials
Mar-14-17 02:42PM  Sunesis Pharmaceuticals, Inc. :SNSS-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017 Capital Cube
02:42PM  Sunesis Pharmaceuticals, Inc. :SNSS-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
Mar-10-17 02:19PM  Edited Transcript of SNSS earnings conference call or presentation 9-Mar-17 4:00pm GMT Thomson Reuters StreetEvents
Mar-09-17 11:00AM  Sunesis Pharmaceuticals Inc Earnings Call scheduled for 11:00 am ET today
09:31AM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
09:15AM  Spectrum (SPPI) Q4 Loss Narrower than Expected, Sales Beat
07:20AM  Sunesis reports 4Q loss Associated Press
Sunesis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalently binding inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies. The company also engages in developing TAK-580, a pan-Raf inhibitor program in combination with various anticancer agents for the treatment of advanced solid tumor cancers in adult patients; SNS-510, which is in preclinical pharmacology and toxicology studies for the treatment of solid tumor and hematologic malignancies; and vosaroxin, an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). In addition, it is developing vosaroxin, which is in Phase 2 trial with decitabine for treatment of diagnosed acute AML or myelodysplastic syndrome (MDS); Phase 1/2 trial with azacitidine for treatment of MDS; Phase 2 trial with infusional cytarabine for treatment of AML; Phase 1/2 trial in adult patients with previously treated intermediate-2 or high-risk MDS; and Phase 1/2 trial with cytarabine tested as consolidation therapy. The company has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of phosphoinositide-dependent kinase-1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Quinn William P.CFO,Sr.V.P. Finance, Corp.Dev.Dec 10Buy0.4740,00018,80052,000Dec 12 04:57 PM